Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gauri R Varadhachary

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2018
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With ImmunotherapyChristine M Parseghian, Madhavi Patnana, Priya Bhosale, et al.
Annals of Surgery|July 6, 2019
Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic CancerGiampaolo Perri, Laura Prakash, Huamin Wang, et al.
Acta Oncologica (Stockholm, Sweden)|January 23, 2015
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancerAwalpreet S Chadha, Esengul Kocak-Uzel, Prajnan Das, et al.
The American Journal of Surgical Pathology|July 23, 2015
Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal AdenocarcinomaLi Liu, Matthew H Katz, Sun M Lee, et al.
Pancreas|September 14, 2017
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant ChemotherapyReza Nejati, Jennifer B Goldstein, Daniel M Halperin, et al.
Annals of Surgical Oncology|January 20, 2012
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapyChing-Wei D Tzeng, Jason B Fleming, Jeffrey E Lee, et al.
Cancer|December 20, 2011
Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiationJiansheng Wang, Jeannelyn S Estrella, Lan Peng, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|September 3, 2013
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancerChing-Wei D Tzeng, Aparna Balachandran, Mediha Ahmad, et al.
Journal for Immunotherapy of Cancer|May 26, 2022
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trialKanwal P Raghav, Bettzy Stephen, Daniel D Karp, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 31, 2012
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resectionRyan M Thomas, Mark J Truty, Graciela M Nogueras-Gonzalez, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2018
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With ImmunotherapyChristine M Parseghian, Madhavi Patnana, Priya Bhosale, et al.
Annals of Surgery|July 6, 2019
Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic CancerGiampaolo Perri, Laura Prakash, Huamin Wang, et al.
Acta Oncologica (Stockholm, Sweden)|January 23, 2015
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancerAwalpreet S Chadha, Esengul Kocak-Uzel, Prajnan Das, et al.
The American Journal of Surgical Pathology|July 23, 2015
Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal AdenocarcinomaLi Liu, Matthew H Katz, Sun M Lee, et al.
Pancreas|September 14, 2017
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant ChemotherapyReza Nejati, Jennifer B Goldstein, Daniel M Halperin, et al.
Annals of Surgical Oncology|January 20, 2012
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapyChing-Wei D Tzeng, Jason B Fleming, Jeffrey E Lee, et al.
Cancer|December 20, 2011
Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiationJiansheng Wang, Jeannelyn S Estrella, Lan Peng, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|September 3, 2013
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancerChing-Wei D Tzeng, Aparna Balachandran, Mediha Ahmad, et al.
Journal for Immunotherapy of Cancer|May 26, 2022
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trialKanwal P Raghav, Bettzy Stephen, Daniel D Karp, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 31, 2012
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resectionRyan M Thomas, Mark J Truty, Graciela M Nogueras-Gonzalez, et al.
Pageof 12